NCT01125527View on ClinicalTrials.gov

Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children

PHASE3CompletedINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

April 30, 2010

Conditions
Haemophilus Influenzae Type b (Hib) Infection
Interventions
BIOLOGICAL

Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)

a single dose was administered

BIOLOGICAL

Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)

a single dose was administered

Trial Locations (1)

Unknown

Hebei Province

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY